Molecular advances in pancreatic cancer

Digestion

Volumn 58, Issue 6, 1997, Pages 550-556

  Lemoine, Nicholas R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Gene therapy; Oncogene; Pancreatic cancer; Tumour suppressor gene

Indexed keywords

PRODRUG; TRYPSINOGEN; TUMOR ANTIGEN;

CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CONFERENCE PAPER; DRUG ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENETIC PREDISPOSITION; GERM LINE; HUMAN; IMMUNOMODULATION; MOLECULAR GENETICS; NONHUMAN; ONCOGENE; PANCREAS CANCER; POINT MUTATION; PRIORITY JOURNAL; SUICIDE GENE; TUMOR SUPPRESSOR GENE;

GENES, TUMOR SUPPRESSOR; HUMANS; MOLECULAR BIOLOGY; ONCOGENES; PANCREATIC NEOPLASMS;

EID: 0030687903     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201500     Document Type: Article

References (70)

1. Lemoine NR: Molecular pathology of pancreatic duct neoplasms: in Sirica A, Longnecker DS(eds): Biliary and Pancreatic Ductal Epithelium: Palhobiology and Pathophysiology, New York, Dekker, 1997, pp 505-526.
2. McCormick CSF, Lemoine NR: Molecular biology: Diagnostic and therapeutic potentials; in Howard JM (ed): Surgical Diseases of the Pancreas, Media, Williams & Wilkins, 1997, in press.
3. Lcmoine NR: Genetic intervention for the treatment and prevention of pancreatic cancer, Dig Surg 1995;11:170-177.
4. Lynch HT, Smyrk T, Kern SE, H ruban RH, Lightdale CJ, Lemon SJ, Lynch JF, Fusaro LR, Fusaro RM, Ghadirian P: Familial pancreatic cancer: A review, Semin Oncol 1996:23:251-275.
5. Lynch HT, Fusaro RM: Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome, Pancreas 1991:6:127-131.
6. Whelan AJ, Bartsch D, Goodfcllow PJ: Brief report: A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene, N Engl J Med 1995:333:975-977.
7. Goldstein AM, Fraser MC, Strucwing JP, Hus-sussian CJ, Ranadc K, Zametkin DP, Fontaine LS, Organic SM, Draco poli NC, Clark WH Jr., et al: Increased risk of pancreatic cancer in melanoma-prone kindreds with pl6INK4 mutations, N Engl J Med 1995:333:970-974.
8. Gullick WJ, Handvsidc AH: Pre-implantation diagnosis of inherited predisposition to cancer, Eur J Cancer 1994;13:2030-2032.
9. Whitcomb DC, Gorry MC, Preston RA, Furcy W, Sossenheimer MJ, Ulrich CD, Martin SP, Gates I.K, Amann ST, Toskes PP, Liddle R, McGrath K, Uomo G, Post JC, Ehrlich GD: Hereditary pancreatitis is caused by a mutation in the cationic trypsinogcn gene, Nature Genet 1996:14:141-145.
10. Kattwinkcl J, Lapey A, Di Santagnese PA, Edwards WA: Hereditary pancreatitis: Three new kindreds and a critical review of the literature, Pediatrics 1973:51:55-69.
11. Friend SH: Breast cancer susceptibility testing: realities in the post-genomic era, Nature Genetics 1996:13:16-17.
12. Porter A: Gene targeting as an approach to gene therapy; in Lemoine NR, Cooper DN (eds): Gene Therapy, Oxford, Bios 1996, pp 169-190.
13. Jones PH, Harper S, Watt FM: Stem cell patterning and fate in human epidermis, Cell 1995:80:83-93.
14. Barton CM, Staddon SL, Hughes CM, Hall PA, O’sullivan C, Klöppel G, Theis B, Russell RC, Ncoptolcmos JP, Williamson RCN, Lane DP, Lemoine NR: Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer, Br J Cancer 1991:64:1076-1082.
15. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, lacono C, Hirohashi S: Pancreatic adenocarcinomas frequently show p53 gene mutations, Am J Pathol 1993:142:1534-1543.
16. Simon B, Weinei R, Hohne M, Watz J, Schmidt J, Kortner G, Arnold R: Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic cancer, Gastroenterology 1994:106:1645-1651.
17. Ruggeri BA, Klein-Szanto AJP, Huang LY, Lang D: P53 and RB-1 tumor suppressor gene expression and alterations in human pancreatic cancer, Int J Pancreatol 1994:16:193-196.
18. Kalthoff H, Schmiegcl W, Roeder C, Kasche D, Schmidt A, Lauer G, Thiele HG, Honold G, Pantel K, Riethmuller G, Scherer E, Maurer J, Maackc H, Deppert W: p53 and K-RAS alterations in pancreatic epithelial cell lesions, Oncogene 1993;8:289-298.
19. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE: p53 mutations in pancreatic carcinoma and evidence of common homocopolymer tracts in DNA microdeletions, Cancer Res 1994;54:3025-3033.
20. Berrozpc G, Schaeffer J, Peinado MA, Real FX, Perucho M: Comparative analysis of mutations in the p53 and K-ras genes in pancreas cancer, Int J Cancer 1994;58:185-191.
21. Levine AJ, Perry ME, Chang A, Silver A, Dittmcr D, Wu M, Walsh D: The 1993 Waller Huber Lecture: The role of the p53 tumoursup-pressor gene in tumourigenesis, Br J Cancer 1994:69:409-416.
22. Chen PL, Chen YM, Bookstein R, Lee WH: Genetic mechanisms of tumor suppression by the human p53 gene, Science 1990:250:1576-1580.
23. Frcbourg T, Sadclain M, Ng YS, Kassel J, Friend SH: Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype, Cancer Res 1994:54:878-881.
24. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model [see comments], J Natl Cancer Inst 1994:86:1458-1462.
25. Wills KN, Maneval DC, Menzel P, Harris MP, Suljipto S, Vaillancourt MT, Huang WM, Johnson DE, Anderson SC, Wen SF, et al: Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer, Hum Gene Thcr 1994; 5:1079-1088.
26. Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA: High-efficicncy gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus, Cancer Gene Ther 1994:1:5-13.
27. Zhang WW, Roth JA: Anti-oneogcne and tumor suppressor gene therapy: Examples from a lung cancer animal model, In Vivo 1994:8: 755-769.
28. Liu TJ, Zhang WW, Taylor DL, Roth JA, Gocpfert H, Clavman GL: Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus, Cancer Res 1994:54: 3662-3667.
29. dayman GL, Trapnell BC, Mitlercder N, Liu TJ, Eicher S, Zhang S, Shilliioe EJ: Transduction of normal and malignant oral epithelium by an adenovirus vector: the effect of dose and treatment time on transduction efficiency and tissue penetration, Cancer Gene Ther 1995:2: 105-111.
30. dayman GL, cl Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, Liu TJ: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma, Cancer Res 1995:55:1-6.
31. Liu TJ, el Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL, dayman GL: Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck, Cancer Res 1995:55: 3117-3122.
32. dayman GL, Liu TJ, Overholt SM, Mobley SR, Wang M, Janot F, Goepfert H: Gene therapy for head and neck cancer, Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21), Arch Otolaryngol Head Neck Surg 1996; 122:489-493.
33. Yang C, Cirielli C, Capogrossi MC, Passaniti A: Adenovirus-mediated wild-tvpc p53 expression induces apoptosis and suppresses tumori-genesis of prostatic tumor cells, Cancer Res 1995:55:4210-4213.
34. Eastham JA, Hall SJ, Sehgal I, Wang J, Timmc TL, Yang G, Connell Crowley L, Elledge SJ, Zhang WW, Harper JW, et al: In vivo gene therapy with p53 or p2l adenovirus for prostate cancer, Cancer Res 1995:55:5151-5155.
35. Bookstein R, Demers W, Gregory R, Maneval D, Park J, Wills K: p53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer, Semin Oncol 1996:23:66-77.
36. Werthman PE, Drazan KE, Rosenthal JT, Khalili R, Shakcd A: Adcnoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer, J Urol 1996:155:753-756.
37. Hamada K, Alemany R, Zhang WW, Hittel-man WN, Lotan R, Roth JA, Mitchell MF: Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer, Cancer Res 1996:56:3047-3054.
38. Drazan KE, Shen XD, Csete ME, Zhang WW, Roth JA, Busuttil RW, Shaked A: In vivo adc-noviral-mediated human p53 tumor suppressor gene transfer and expression in rat liver after resection, Surgery 1994; 116:197-203.
39. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen Schaub l.B, Roth JA: Induction of chcmosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene, Cancer Res 1994:54: 2287-2291.
40. Harper J, Adami G, W'ei N, Keyormarsi K, Elledge S: The p21 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-depen-dent kinases, Cell 1993;75:805-816.
41. El-Dcirv W, Tokino T, Velculcscu V, Levy D, Parsons R, Trent J, Lin D, Mercer W, Kinzler K, Vogclstein B: WAFI, a potential mediator of p53 tumor suppression, Cell 1993:75:817-825.
42. Caldas C, Hahn SA, da Costa LT, Redston MS, Schulte M, Seymour AB, Weinstein CL, Hru-ban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p 16 (MTSI) gene in pancreatic adenocarcinoma, Nature Genet 1994;8:27-31.
43. Liu Q, Yan Y-X, McClure M, Nakagawa H, Fujimura F, Rustgi AK: MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines, Oncogene 1995;10:619-622.
44. Bartsch D, Shcvlin DW, Tung WS, Kisker O, Wells SA, Goodfellow PJ: Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas, Genes Chromosom Cancer 1995:14: 189-195.
45. Nauntann M, Savitskaia N, Eilert C, Schramm A, Kalthoff H, Schmiegel W: Frequent codeie-lion of PI 6/MTS 1 and P15/MTS2 and genetic alterations in pl6/MTSl in pancreatic tumors, Gastroenterology 1996:110:1215-1224.
46. Yeager T, Stadler W, Beiair C, Puthenveeltil S, Olapadc O, Reznikoff C: Increased pl6 levels correlate with pRS alterations in human urothelial cells, Cancer Res 1995:55:493-497.
47. Mukhopadhyay T, Tainsky M, Cavender AC, Roth JA: Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA, Cancer Res 1991:51:1744-1748.
48. Yoshida T, Aoki K: Gene therapy for pancreatic cancer, Tanpakushitsu Kakusan Koso 1995: 40:2727-2731.
49. Aoki K, Yoshida T, Sugimura T, Terada M: Liposome-mediated in vivo gene transfer of antiscnsc K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity, Cancer Res 1995:55:3810-3816.
50. Bayevcr E, Iversen P: Oligonucleotides in the treatment of leukemia, Hematol Oncol 1994: 12:9-14.
51. Bishop MR, Iversen PL, Baycvcr E, Sharp JG, Greiner TC, C'opple BL, Ruddon R, Zon G, Spinolo J, Arncson M, Armitagc JO, Kcssinger A: Phase 1 trial of an antisense oligonucleotide OL(l)p53 in hematologic malignancies, J Clin Oncol 1996;14:1320-1326.
52. Barton CM, Lemoine NR: Antiscnsc oligonucleotides directed against TP53 have antiproliferative effects unrelated to effects on p53 expression, Br J Cancer 1995;71:429-437.
53. Cai DW, Mukhopadhyay T, Roth JA: Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA, Cancer Gene Ther 1995;2:199-205.
54. Colomer R, Lupcr R, Bacus SS, Gelmann EP: ErbB2 antiscnsc oligonucleotides inhibit the proliferation of breast carcinoma cells with ErbB2 oncogene amplification, Br J Cancer 1994:70:819-825.
55. Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ, Lemoine NR: The c-erbB-2 proto-oncogene in human pancreatic cancer, J Pathol 1990;161:195-200.
56. Ebbinghaus SW, Gee JE, Rodu B, Mayfield CA, Sanders G, Miller DM: Triplex formation inhibits HER-2/neu transcription in vitro, J Clin Invest 1993:92:2433-2439.
57. Kitada S, Takavama S, De Riel K, Tanaka S, Reed JC: Reversal of chcmoresistancc of lymphoma cells by antisensc-mediatcd reduction of bcl-2 gene expression, Antiscnsc Res Dev 1994;4:71-79.
58. Gao WY, Han FS, Storm C, Egan W, Cheng YC: Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNasc H: Implications for antiscnsc technology, Mol Pharmacol 1992;41:223-229.
59. Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS, Kramer TB, et al: The antiproliferative activity of c-myb and c-myc antiscnsc oligonucleotides in smooth muscle cells is caused by a nonantisensc mechanism, Proc Natl Acad Sci USA 1995:92:4051-4055.
60. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA: Phosphorothioate ol-igodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix, J Biol Chem 1995;270:2620-2627.
61. Krieg AM: CpG DNA: A pathogenic factor in systemic lupus erythematosus? J Clin Immunol 1995:15:284-292.
62. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klin-ntan DM: CpG motifs in bacterial DNA trigger direct B-ccll activation, Nature 1995:374:546-549.
63. Yamamoto T, Yamamoto S, Kataoka T, Toku-naga T: Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length, Antisense Res Dev 1994:4:119-122.
64. Yamamoto T, Yamamoto S, Kataoka T, Toku-naga T: Lipofection of synthetic oligodeoxvri-bonucleotide having a palindromic sequence of AACGTT to murine splcnocytes enhances interferon production and natural killer activity, Microbiol Immunol 1994;38:831-836.
65. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR: Gene therapy for cancer using tumour-specific prodrug activation, Gene Ther 1994;1:170-175.
66. Sikora K, Harris J, Hurst H, Lemoine NR: Therapeutic strategies using c-erbB-2 promoter-controlled drug activation, Ann NY Acad Sci 1994:716:115-124.
67. Austin EA, Huber BE: Localization of thecod A gene on the Escherichia coli chromosome, J Bacteriol 1993;175:3685-3686.
68. Richards CA, Austin EA, Huber BE: Transcriptional regulatory sequences of carcinoem-brvonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy, Hum Gene Ther 1995;6:881-893.
69. Richards CA, Huber BE: Generation of a transgenic model for retrovirus-mediated gene therapy for hepatocellular carcinoma is thwarted by the lack of transgene expression, Hum Gene Ther 1993;4:143-150.
70. Zousir F, Zerowski S, Sikora J, Szmeja J, He-dm A, Hammarstrom S: I umor specificity of antibodies to carcinoembrvonic antigen, Im-munohistochemical analysis, Tumor Biol 1990:11:5-19.